Kymab secures $100m and two new Chinese backers

By Gareth Macdonald contact

- Last updated on GMT

Cytovance facility in Oklahoma City, US likely to play role in production of Kymab mAbs (source Google images)
Cytovance facility in Oklahoma City, US likely to play role in production of Kymab mAbs (source Google images)

Related tags: China, Monoclonal antibodies

Antibody developer Kymab has secured $100m from existing backers and new China-based investors Hepalink and ORI Healthcare Fund.

Kymab will use the funds to pay for development of its therapeutic monoclonal antibodies (mAb) the first of which, the Graft-versus-host disease (GvHD) candidate KY1005, is due to enter clinical trials in 2017.

Hepalink is a Shenzhen, China-based supplier of heparin sodium active pharmaceutical ingredient (API). It entered the large molecule sector last year​ when it acquired Cytovance Biologics for $206m (€183m).

Through Cytovance, Hepalink operates a mammalian and microbial cell development and manufacturing facility in Oklahoma City, US.

Kymab CEO, David Chiswell told us “Hepalink has a biological strategy and are actively developing antibodies for the Chinese market in addition they have antibody manufacturing facilities in the US. 

“We hope to collaborate together in the future either through using their manufacturing facilities in the US or developing some of our antibodies in China. Ori Fund have a large network in China and we will work with them to ​leverage their expertise.”

China, where both Hepalink and ORI are based, is a key market for UK-based Kymab according to Chiswell.

“Since Kymab was established, we have been targeting the Chinese market we have a network of contacts in the region who understand and appreciate the power of our platform​.”

Related news

Show more

Related products

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Related suppliers

Follow us

Products

View more

Webinars